Mutations in the pantothenate kinase of Plasmodium falciparum confer diverse sensitivity profiles to antiplasmodial pantothenate analogues by Tjhin, Erick T. (R19294) et al.
RESEARCH ARTICLE
Mutations in the pantothenate kinase of
Plasmodium falciparum confer diverse
sensitivity profiles to antiplasmodial
pantothenate analogues
Erick T. Tjhin1, Christina Spry1, Alan L. Sewell2, Annabelle Hoegl3, Leanne Barnard4, Anna
E. Sexton5, Ghizal Siddiqui5, Vanessa M. Howieson1, Alexander G. Maier1, Darren
J. Creek5, Erick Strauss4, Rodolfo Marquez2,6, Karine Auclair3, Kevin J. Saliba1,7*
1 Research School of Biology, The Australian National University, Canberra, Australia, 2 Department of
Chemistry, University of Glasgow, Glasgow, United Kingdom, 3 Department of Chemistry, McGill University,
Montreal, Quebec, Canada, 4 Department of Biochemistry, Stellenbosch University, Matieland, South Africa,
5 Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia, 6 Department of




The malaria-causing blood stage of Plasmodium falciparum requires extracellular pantothe-
nate for proliferation. The parasite converts pantothenate into coenzyme A (CoA) via five
enzymes, the first being a pantothenate kinase (PfPanK). Multiple antiplasmodial pantothe-
nate analogues, including pantothenol and CJ-15,801, kill the parasite by targeting CoA bio-
synthesis/utilisation. Their mechanism of action, however, remains unknown. Here, we
show that parasites pressured with pantothenol or CJ-15,801 become resistant to these
analogues. Whole-genome sequencing revealed mutations in one of two putative PanK
genes (Pfpank1) in each resistant line. These mutations significantly alter PfPanK activity,
with two conferring a fitness cost, consistent with Pfpank1 coding for a functional PanK that
is essential for normal growth. The mutants exhibit a different sensitivity profile to recently-
described, potent, antiplasmodial pantothenate analogues, with one line being hypersensi-
tive. We provide evidence consistent with different pantothenate analogue classes having
different mechanisms of action: some inhibit CoA biosynthesis while others inhibit CoA-uti-
lising enzymes.
Author summary
The coenzyme A (CoA) biosynthetic pathway is under investigation as a target for the
development of drugs aimed at several infectious agents, including malaria parasites. To
synthesise CoA, the parasite scavenges the essential precursor pantothenate (vitamin B5).
Several pantothenate analogues possess potent (nM) activity against the parasite, but their
exact mechanism of action is unknown. We have generated mutant parasites that are
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resistant or hypersensitive to various pantothenate analogues. These parasites harbour
mutations in a gene we now show codes for the first enzyme in the CoA biosynthesis path-
way. This enzyme is not the target of the analogues, but instead converts them into anti-
metabolites that, depending on the analogue, either inhibit a CoA biosynthesis enzyme or
downstream CoA-utilising enzymes.
Introduction
In recent years, the effort to roll back malaria has shown encouraging progress through the
increased use of insecticide-treated mosquito nets, improved diagnostics and artemisinin-
based combination chemotherapies (ACTs) [1]. Evidence of this includes the decreasing
worldwide malaria incidence (266 million cases in 2005 down to 212 million cases in 2015)
and mortality (741,000 deaths in 2005 down to 429,000 deaths in 2015) over the past decade
[1]. However, there is an alarming trend of ACT-resistant parasites emerging in multiple
Asian countries where the disease is endemic [2]. Recently, there have also been multiple
reports of patients contracting ACT-resistant Plasmodium falciparum malaria from various
African countries [3,4], which exemplify the clear risk of artemisinin resistance developing in
the continent. This threat to the efficacy of ACTs highlights the requirement for a new
armoury of antimalarial medicines, with several compounds representing different chemo-
types entering the preclinical trial stage. However, the antimalarial drug-discovery pipeline is
reliant on just a few known drug targets and the probability of successfully producing a new
blood-stage medicine remains low [5]. In order to manage the threat of parasite drug resis-
tance, there needs to be a continued effort to identify new classes of antimalarials. One meta-
bolic pathway that has garnered recent interest for drug-development is the parasite’s
coenzyme A (CoA) biosynthetic pathway [6,7].
Early seminal studies have shown that the asexual stage of intra-erythrocytic P. falciparum
absolutely requires an exogenous supply of vitamin B5 (pantothenate; Fig 1) for survival [7–9].
Pantothenate is taken up by the parasite [10,11] and converted into CoA, an essential cofactor
for many metabolic processes [7]. This conversion is catalysed by a series of five enzymes, the
first of which is pantothenate kinase (PfPanK), an enzyme that phosphorylates pantothenate to
form 4’-phosphopantothenate [11]. By performing this step, the parasite traps pantothenate
within its cytosol and commits it to the CoA biosynthetic pathway [10]. The additional four
steps are, in turn, catalysed by phosphopantothenoylcysteine synthetase (PfPPCS), phospho-
pantothenoylcysteine decarboxylase (PfPPCDC), phosphopantetheine adenylyltransferase
(PfPPAT) and dephospho-CoA kinase (PfDPCK) [6]. Putative genes coding for each of the
enzymes in the pathway (with several enzymes having multiple putative candidates) have been
identified in the P. falciparum genome [12,13] and have also been shown to be transcribed dur-
ing the intraerythrocytic stage of the parasite’s lifecycle [14]. In order to capitalise on the path-
way as a potential target for drug-discovery, however, it is crucial to ascertain the exact
identity of each of these putative genes. This will allow the process to become more efficient
and targeted.
Investigations aimed at discovering antiplasmodial agents that act by interfering with the
parasite’s CoA biosynthetic pathway identified several antiplasmodial pantothenate analogues,
including pantothenol (PanOH) and CJ-15,801 [9,15,16] (see Fig 1 for structures). Subsequent
studies identified pantothenamides as antiplasmodial pantothenate analogues with substan-
tially increased potency [17–19]. Unfortunately pantothenamides are unstable in vivo because
they are degraded by the serum enzyme pantetheinase [17]. Recent reports of structural
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optimisations of lead pantothenamides have described two compounds, N5-trz-C1-Pan (com-
pound 1e in Howieson et al. [20]) and N-PE-αMe-PanAm (see Fig 1 for structures), that are
potent antiplasmodials (with nanomolar IC50 values) and also resistant to pantetheinase-medi-
ated degradation [20,21]. However, although these compounds have been shown to target
CoA biosynthesis or utilisation, their exact mechanism(s) of action has not been elucidated.
In this study, we have used continuous drug-pressuring with PanOH or CJ-15,801 to gener-
ate a number of P. falciparum parasite lines that are several-fold resistant to these pantothenate
analogues. Whole-genome sequencing revealed mutations in one of the two putative Pfpank
genes of all of the clones, Pfpank1. Complementation experiments confirmed that these muta-
tions are responsible for the resistance phenotypes. Characterisation of the effects of the muta-
tions on parasite growth in culture and also PfPanK function, generated data consistent with
the mutated gene coding for an active PanK in P. falciparum and with the gene being essential
for normal parasite development during the intraerythrocytic stage of its lifecycle. Additional
characterisation of the PanOH and CJ-15,801-resistant lines revealed that antiplasmodial pan-
tothenate analogues have at least two distinct mechanisms of action, targeting CoA biosynthe-
sis or utilisation. Both of these mechanisms can be influenced by the Pfpank1 mutations
identified here. Furthermore, our study provides genetic evidence validating the importance of
the metabolic activation of pantothenate analogues in the antiplasmodial activity of these
compounds.
Materials and methods
Parasite culture and lysate preparation
P. falciparum parasites were maintained in RPMI 1640 media supplemented with 11 mM glu-
cose (final concentration of 22 mM), 200 μM hypoxanthine, 24 μg/mL gentamicin and 6 g/L
Albumax II (referred to as complete medium) as previously described [22]. Clonal parasite
populations were generated through limiting dilution cloning as reported previously [23], with
modifications. Parasite lysates were prepared from saponin-isolated mature trophozoite-stage
parasites as described previously [10].
Fig 1. Structures of pantothenate and the pantothenate analogues used in this study.
https://doi.org/10.1371/journal.ppat.1006918.g001
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Plasmid preparation and parasite transfection
Several plasmid constructs were generated through the course of this study to be used for dif-
ferent lines of investigations. The strategies used to generate the Pfpank1-pGlux-1, Pfpank1-
stop-pGlux-1 and ΔPfpank1-pCC-1 plasmids are detailed in the SI and the primers used in
these strategies are listed in S1 Table. The constructs were transfected into ring-stage parasites
and positive transfectants were selected by introducing WR99210 (10 nM) [24].
Compound synthesis
The pantothenate analogues CJ-15,801 [25], N5-trz-C1-Pan [26] and N-PE-αMe-PanAm [21],
used in this study were synthesised as reported previously.
SYBR Safe-based parasite proliferation assay
The effect of various compounds on the in vitro proliferation of the different parasite lines
were tested using a previously-reported SYBR Safe-based fluorescence assay [17], with minor
modifications (SI). In vitro pantothenate requirement experiments were performed similarly
(SI), except instead of a test compound, ring stage-infected erythrocytes were incubated in
pantothenate-free complete RPMI 1640 medium (made complete as described above; Athena
Enzyme Systems) supplemented with 2-fold serial dilutions of pantothenate. IC50 and SC50
(defined in the Results section) values were determined from the sigmoidal curves fitted to
each data set using nonlinear least squares regression (SI).
Drug pressuring
Two independent drug-pressuring cultures were initiated for each of the pantothenate ana-
logues, PanOH and CJ-15,801. Pressuring was initiated by exposing synchronous ring-stage
Parent line parasites (10 mL culture of 2 or 4% parasitaemia and 2% haematocrit) to either
analogue at the IC50 values obtained for the Parent line at the time (PanOH = 400 μM and CJ-
15,801 = 75 μM). Parasites were then exposed to cycles of increasing drug-pressure that lasted
about 2–4 weeks each (SI). When the pressured parasites became approximately 8 × less sensi-
tive than the Parent line to the selecting analogues, they were cloned and cultured in the
absence of the analogues for the remainder of the study.
Competition assay
In order to compare the fitness of the mutant clones with that of the Parent, we set up three
competition cultures, each containing a mixture of one mutant line and the Parent line. Equal
number of parasites (5 × 108 cells in the first experiment and 2.5 × 108 cells in the second
experiment) from each line were mixed into a single culture. Aliquots (3 to 5 mL) of these cul-
tures were immediately used for a PanOH SYBR Safe-based parasite proliferation assay (to
generate Week 0 data) as described above. The cultures were then maintained under standard
conditions as detailed above for a period of 6 weeks before they were used to perform another
PanOH proliferation assay (to generate Week 6 data).
Whole genome sequencing and variant calling
Next generation whole genome sequencing was performed by the Biomolecular Resource
Facility at the Australian Cancer Research Foundation, the Australian National University.
Samples were sequenced with the Illumina MiSeq platform with version 2 chemistry (2 × 250
base pairs, paired-end reads) Nextera XT Kit (Illumina). To determine the presence of any sin-
gle nucleotide polymorphisms (SNPs) in the genomes of the drug-pressured clones, the
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genomic sequencing data were analysed using an integrated variant calling pipeline, PlaTyPus,
as previously described [27], with minor modifications to resolve operating system incompati-
bility. As PlaTyPus does not detect insertions-deletions polymorphisms (“indels”), the Inte-
grated Genome Viewer (IGV) software (Broad Institute) was used to manually inspect the
gene sequences of all putative enzymes in the CoA biosynthetic pathway for indels.
Quantitative polymerase chain reaction (qPCR)
To determine the proportions of parasites (i.e. Parent versus mutant clone) that make up each
competition culture, we performed qPCR to measure the amount of Parent and mutant geno-
mic DNA (gDNA) at week 0 and week 6 of the competition assay. gDNA was extracted using a
DNeasy Plant Mini Kit (QIAGEN) or QIAamp DNA Blood Midi Kit (QIAGEN) following the
manufacturer’s instructions, unless otherwise specified (detailed in SI). Six different primer
sets were designed, each to detect the specific variants (SNPs or indel) in the wild-type and
mutant Pfpank1 alleles (S1 Table). The qPCRs were performed using QuantiTect 2 × SYBR
Green PCR Master Mix (QIAGEN) essentially as reported previously [28] with the following
specifications: The reactions (20 μL final volume) for “Parent vs PanOH-A” and “Parent vs
PanOH-B” contained 2 μL of 10 ng/μL gDNA stocks while that for “Parent vs CJ-A” contained
4 μL of 10 ng/μL gDNA stocks. The PCR program for “Parent vs PanOH-A” and “Parent vs
CJ-A” entailed an initial DNA polymerase activation step (95˚C for 15 min) followed by 40
cycles of denaturation (94˚C for 15 s), annealing (60 or 55˚C, respectively, for 30 s) and exten-
sion (72˚C for 30 s) with the detection step (green channel) set during the extension step of
each cycle. For “Parent vs PanOH-B” the PCR was programmed as above except that it was set
for 45 cycles, the annealing step was carried out at 58˚C and included an additional detection
step (65˚C for 15 s, green channel) in each cycle. Following each reaction, a melt curve analysis
was performed starting with a temperature that is 1˚C lower than the annealing temperature
and increased to 99˚C at 1˚C/s. Control reactions that each contained defined proportions of
the Parent and mutant gDNA as templates, set at the same final DNA concentration as detailed
above, were included in each qPCR experiment to enable preparation of a standard curve. The
standard curve was generated by plotting the threshold cycle values obtained for the control
reactions against the corresponding log10 gDNA amount and fitting a straight line (y = y0 +ax,
where y denotes threshold cycle value, x denotes log10 DNA amount and a denotes primer effi-
ciency). The concentration of Parent and mutant gDNA in each sample was determined by
comparing their threshold cycle against the appropriate standard curve. All reactions were per-
formed in duplicate.
Generation of PfPanK1 model
The structure of PfPanK1 minus its parasite-specific inserts was predicted by homology
modeling using the AMPPNP and pantothenate-bound human PanK3 structure (PDB ID:
5KPR [29]) as a template. PfPanK1 shares 28% sequence identity with human PanK3 over the
parts of the protein that have been modeled. The model was generated using the one-to-one
threading module of the Phyre2 webserver (available at http://www.sbg.bio.ic.ac.uk/phyre2)
[30].
Confocal microscopy
Erythrocytes infected with trophozoite-stage 3D7 strain P. falciparum parasites expressing
PfPanK1-GFP were observed and imaged either with a Leica TCS-SP2-UV confocal micro-
scope (Leica Microsystems) using a 63 × water immersion lens or a Leica TCS-SP5-UV
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confocal microscope (Leica Microsystems) using a 63 × oil immersion lens. The parasites were
imaged as fixed or live cells as described in the SI.
Attempted disruption of Pfpank1
The Pfpank1 disruption plasmid, ΔPfpank1-pCC-1 (SI), was transfected into wild-type 3D7
strain P. falciparum, and positive transfectants were selected as described above. P. falciparum
parasites have previously been shown to survive equally well in a pantothenate-free complete
RPMI 1640 medium supplemented with100 μM CoA as compared to standard complete
medium, consistent with them having the capacity to take up exogenous CoA, hence bypassing
the need for any PfPanK activity [7]. Therefore, to support the growth of any Pfpank1 gene-
disrupted parasites generated with the ΔPfpank1-pCC-1 construct, parasites were continuously
maintained in complete medium supplemented with 100 μM CoA following transfection. Pos-
itive and negative selection steps (with WR99210 and 5-fluorocytosine (5-FC), respectively)
were performed to isolate ΔPfpank1-pCC-1-transfectant parasites in which the double cross-
over homologous recombination had occurred (detailed in SI).
Southern blot analysis
gDNA samples (~2 μg) extracted from ΔPfpank1-pCC-1-transfectant parasites isolated
through the positive and negative selection steps were digested with the restriction enzyme
AflII (New England Biolabs), before being analysed by Southern blotting using the digoxigenin
(DIG) system (Roche) according to the Roche DIG Applications Manual for Filter Hybridisa-
tion. The results from the Southern blot were confirmed with PCR (the primers used are
shown in S1 Table).
[14C]Pantothenate phosphorylation by parasite lysate
The phosphorylation of [14C]pantothenate by parasite lysates prepared from the Parent and
mutant clonal lines was measured using Somogyi reagent (which precipitates phosphorylated
compounds from solution) as outlined previously [31], with some modifications (detailed in
SI).
Metabolism of N5-trz-C1-Pan
Cultures of predominantly trophozoite-stage P. falciparum-infected erythrocytes (Parent line)
were concentrated to>95% parasitaemia using magnet-activated cell sorting as described else-
where [32]. Following recovery, trophozoite-infected erythrocytes were treated with N5-trz-
C1-Pan (1 μM) or a solvent control (0.01% v/v DMSO) before the metabolites in these samples
were extracted and processed for liquid chromatography-mass spectrometry (LC-MS) analysis.
Metabolite samples were analysed by LC-MS, using a Dionex RSLC U3000 LC system (Ther-
moFisher) coupled with a high-resolution, Q-Exactive MS (ThermoFisher), as described previ-
ously [33] (detailed in SI). LC-MS data were analysed in a non-targeted fashion using the
IDEOM workflow, as described elsewhere [34]. Unique features identified in N5-trz-C1-Pan-
treated samples were manually assessed by visualising high resolution accurate mass LC-MS
data with Xcalibur Quanbrowser (ThermoFisher) software.
PfPanK1 protein levels
To measure PfPanK1 levels, parasite samples were prepared from Parent and mutant cultures
as previously described with minor modifications [35]. Briefly, mature trophozoites were sapo-
nin-isolated from a culture of infected erythrocytes (10% parasitaemia, 2% haematocrit in 30
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mL) by resuspending the pellet in 1 × phosphate buffered saline (PBS; Sigma-Aldrich) contain-
ing 0.05% (w/v) saponin, 1 × complete mini protease inhibitor cocktail (Roche), 20 mM
sodium fluoride and 0.1 mM sodium orthovanadate. The isolated trophozoites were pelleted
(2,000 × g, 8 min), washed (15,850 × g, 30 s, supernatant discarded after each wash) once in 1
mL of the above solution excluding saponin, and twice with 1 mL 1 × PBS. The trophozoite
pellet was then stored at −80˚C until required. For sample processing, a total of 500 μg of pro-
tein, accurately determined using the Pierce BCA protein assay kit (ThermoFisher), was incu-
bated overnight with sequencing-grade trypsin (1:50 dilution; Promega). On the following
day, trypsin activity was quenched using 5% formic acid (FA) and the detergent (sodium deox-
ycholate) used for protein solubilisation was removed. The samples were then dried and resus-
pended in 20 μL of 2% (v/v) acetonitrile (ACN) and 0.1% (v/v) FA for LC-MS/MS analysis.
For facilitating retention-time (RT) alignments among samples, a RT kit [36] (iRT kit, Biog-
nosys) was spiked into all samples (1:20 dilution).
LC-MS/MS was carried out as described previously [35], with minor modifications. Briefly,
samples were loaded at a flow rate of 15 μL/min onto a reversed-phase trap column (100
μm × 2 cm; Acclaim PepMap media, Dionex), which was maintained at a temperature of 40˚C.
Peptides were then eluted from the trap column at a flow rate of 0.25 μL/min through a
reversed-phase capillary column (75 μm × 50 cm; LC Packings, Dionex). The HPLC gradient
was set to 158 min using a gradient that reached 30% ACN after 123 min, then 34% ACN after
126 min, 79.2% ACN after 131 min and 2% ACN after 138 min, at which it was maintained for
a further 20 min. The mass spectrometer was operated in a data-independent acquisition
(DIA) mode with a 25-fixed-window setup of 24 m/z effective precursor isolation over the m/z
range of 375–975 Da.
For Spectronaut processing, raw files were loaded into Spectronaut (version 11, Biognosys)
with an in-house P. falciparum-infected red blood cell library and default settings. Briefly, RT
prediction type was set to dynamic iRT and the correction factor for the window was set to
one. Mass calibration was set to local mass calibration. Interference correction was on MS2
level. The false discovery rate was set to 1% at peptide precursor level. For quantification, the
interference correction was activated and a cross run normalisation was performed using the
total peak area as the normalisation base. A significance filter of 0.01 was used. The peptides
used in the identification and quantitation of PfPanK1 and the four control proteins are listed
in S2 Table.
Statistical analysis
Statistical analysis of means was carried out with unpaired, two-tailed, Student’s t tests using
GraphPad 6 (GraphPad Software, Inc) from which the 95% confidence interval of the differ-
ence between the means (95% CI) was obtained. All regression analysis was done using Sigma-
Plot version 11.0 for Windows (Systat Software, Inc).
Results
Pfpank1 mutations mediate parasite resistance to PanOH and CJ-15,801
The 3D7 P. falciparum strain was cloned through limiting dilution, and a single parasite line
(henceforth referred to as the Parent line) was used to generate all of the subsequent lines
tested in this study (unless otherwise specified). This was done to ensure that all of the parasite
lines generated during the course of this study would share a common genetic background.
Using the Parent line, three independent drug-pressuring cultures were set up (two with
PanOH and one with CJ-15,801). When these parasites had attained approximately 8-fold
decrease in sensitivity (~11–13 weeks of continuous pressuring), they were subsequently
PfPanK1 influences antiplasmodial activity of pantothenate analogues
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006918 April 3, 2018 7 / 30
cloned by limiting dilution and maintained in the absence of drug pressure. In this manner,
three parasite clones were generated: PanOH-A and PanOH-B were generated from the two
independent PanOH-pressured cultures while CJ-A was generated from the CJ-15,801-pres-
sured culture. The clones are significantly resistant (95% confidence interval (CI) exclude 0) to
the pantothenate analogues they were pressured with. The 50% inhibitory concentration
(IC50) values of PanOH against PanOH-A and PanOH-B, and the IC50 value of CJ-15,801
against CJ-A are approximately 7–8-fold higher than those measured against the Parent line
(Fig 2A and 2B and S3 Table). Significant cross-resistance towards the other pressuring ana-
logue was observed for these clones, as compared to the Parent line (95% CI exclude 0). The
PanOH-A and PanOH-B lines were found to be 4–6-fold less sensitive to CJ-15,801 while
CJ-A was found to be 13-fold less sensitive to PanOH (Fig 2A and 2B and S3 Table). To
ensure that the clones did not develop a general drug-resistance phenotype during the selec-
tion process, we tested their sensitivity to chloroquine, an antiplasmodial with a mechanism of
action that is unrelated to the parasite’s CoA biosynthetic pathway [37]. We found that all of
the drug-pressured lines have chloroquine IC50 values that are indistinguishable from that of
the Parent line (95% CI include 0; Fig 2C and S3 Table).
The PanOH and CJ-15,801 resistance phenotypes observed in the clones were stable for sev-
eral months of continuous culture in the absence of the pressuring analogue ( 3 months),
consistent with a genetic alteration in these parasites. To determine the mutation(s) responsi-
ble for these phenotypes, gDNA was extracted from each clone and subjected to whole genome
sequencing. All of the drug-resistant clones were found to harbour a unique mutation in the
putative pantothenate kinase gene, Pfpank1 (PF3D7_1420600), as shown in Fig 3A. Other
non-synonymous mutations were detected for each clone (S4 Table) but we did not find
another gene that is mutated in all three clones. The mutation found in the Pfpank1 of
PanOH-A results in the substitution of Asp507 for Asn. The other two drug-resistant clones
have a mutation at position 95 of the protein: the Pfpank1 of PanOH-B harbours a deletion of
an entire codon leading to a loss of Gly from the PfPanK1 protein, while the PfPanK1 of CJ-A
has a Gly to Ala substitution. Since the structure of PfPanK1 has not yet been resolved, we gen-
erated a three-dimensional model in order to map the mutations within the enzyme. Fig 3B
shows a PfPanK1 model structure (pink) based on the solved structure of human PanK3 in
complex with adenylyl-imidodiphosphate (AMPPNP) and pantothenate (PDB ID: 5KPR),
overlaid on this structure (blue). The spheres shown in the model indicate the positions of
the mutated residues, while the bound AMPPNP and pantothenate indicate the active site of
the enzymes. Although the mutations are far apart in the primary amino acid sequence of
PfPanK1, they are positioned in closer proximity to each other in the folded protein and are
situated adjacent to the active site.
To confirm that the resistance phenotypes observed for the clones are directly caused by the
mutations in Pfpank1, each clone was transfected with an episomal plasmid (Pfpank1-stop-
pGlux-1) that enables the parasites to express the wild-type copy of Pfpank1 (in addition to the
endogenous mutated copy). These complemented lines are indicated with a superscripted “+-
WTPfPanK1”. From Fig 4 (and S3 Table), it can be observed that the complemented mutant
clones (grey bars) are significantly less resistant to PanOH (Fig 4A) and CJ-15,801 (Fig 4B)
compared to the non-complemented mutant clones (black bars; 95% CI exclude 0). As
expected, the relative sensitivity of the mutant clones to chloroquine is unchanged by the pres-
ence of the PfPanK1-encoding plasmid (95% CI include 0; Fig 4C). Transfection of the PfPan-
K1-encoding plasmid into the Parent line did not alter its sensitivity to PanOH, CJ-15,801 or
chloroquine (95% CI include 0; S3 Table). These data are consistent with the mutations
observed in Pfpank1 being responsible for the resistance phenotype observed in the mutant
clones. An alternative strategy to confirm that the mutant PfPanK1 is responsible for the
PfPanK1 influences antiplasmodial activity of pantothenate analogues
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006918 April 3, 2018 8 / 30
PfPanK1 influences antiplasmodial activity of pantothenate analogues
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006918 April 3, 2018 9 / 30
Fig 2. Percentage proliferation of parasites from the Parent (white circles), PanOH-A (black triangles), PanOH-B
(black squares) and CJ-A (black diamonds) lines in the presence of (a) PanOH, (b) CJ-15,801 or (c) chloroquine.
Drug-pressured lines were generated by exposing Parent line parasites to 11 − 13 weeks of continuous drug-pressuring
with either PanOH (for PanOH-A and PanOH-B) or CJ-15,801 (for CJ-A), followed by limiting dilution cloning.
Values are averaged from 4 independent experiments, each carried out in triplicate. All error bars represent SEM.
Error bars are not visible if smaller than the symbols.
https://doi.org/10.1371/journal.ppat.1006918.g002
Fig 3. Mutations in Pfpank1 and the affected residues within the PfPanK1 protein. (a) The single nucleotide polymorphisms detected in
the Pfpank1 gene (accession number: PF3D7_1420600) of PanOH-A, PanOH-B and CJ-A, and the corresponding amino acid changes in the
PfPanK1 protein. (b) A three-dimensional homology model of the PfPanK1 protein (pink) based on the solved structure of human PanK3
(PDB ID: 5KPR), overlaid on the human PanK3 structure in its active conformation (blue), with an ATP analogue (AMPPNP; carbon atoms
coloured green) and pantothenate (carbon atoms coloured yellow) bound. PfPanK1 shares 28% sequence identity with human PanK3 over
the parts of the protein that have been modeled. Red spheres indicate the residues (G95 and D507) affected by the mutations in the parasite
proteins. Human PanK3 has been shown to exist as a dimer. Here, individual monomers are shown in different shades of pink and blue.
https://doi.org/10.1371/journal.ppat.1006918.g003
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observed phenotypes would be to express the mutant forms of PfPanK1 in the Parent line.
This has not, however, been attempted.
Pfpank1 mutations impair parasite proliferation
We performed a competition assay to determine whether the Pfpank1 mutations impart a fit-
ness cost to the parasite clones. Each of the competition cultures was set up by mixing an equal
number of parasites from the Parent line and one of the mutant clonal lines, and was main-
tained under standard conditions for a period of 6 weeks (Fig 5A). The sensitivity of each com-
petition culture to PanOH was tested on the day the lines were mixed (Week 0) and again at
the end of the 6-week period (Week 6). As expected, each Week 0 (dashed line) PanOH dose-
response curve is between those obtained for the Parent and the respective mutant clone (dot-
ted lines). A shift of the dose-response curve obtained at week 6 (solid line) towards the dose-
response curve of the Parent line would indicate that the mutant PfPanK1 imparts a fitness
cost on the clone. As shown in Fig 5B, the Week 6 curve for the PanOH-A competition culture
only exhibits a marginal leftward shift from Week 0, whereas those for PanOH-B (Fig 5C) and
CJ-A (Fig 5D) exhibits a more substantial shift, almost reaching the dose-response curve of the
Parent line (dotted line, white circles). These trends are supported by qPCR analysis designed
to determine the proportions of mutant versus Parent gDNA at week 0 and week 6 (S1 Fig).
These results are consistent with the mutations at position 95 in the PfPanK1 of PanOH-B and
CJ-A having a greater negative impact on the in vitro growth of the parasites. We also investi-
gated the importance of PfPanK1 expression for parasite growth by attempting to disrupt the
Pfpank1 locus in wild-type 3D7 parasites through homologous recombination (S2A Fig).
However, using Southern blots, we failed to detect the presence of transfectants with the
expected gene-knockout integration event (S2B Fig), consistent with this gene being essential
during the parasite’s intraerythrocytic stage. The lack of integration of the knockout construct
into the PfPanK1 locus, even in a small sub-population of the parasite culture, was confirmed
using PCR (S2C Fig).
PfPanK1 is a functional pantothenate kinase located within the parasite
cytosol
The phosphorylation of radiolabelled pantothenate by lysates prepared from each of the
mutant clones and the Parent line was measured to determine if the mutations in the putative
Pfpank1 gene affect PanK activity, and hence whether the gene codes for a functional PanK.
As shown in Fig 6, at the end of the 75 min time-course, the lysate prepared from PanOH-A
phosphorylated approximately 3 × more [14C]pantothenate than the lysate prepared from the
Parent line, while the lysate of PanOH-B generated about 3 × less phosphorylated [14C]panto-
thenate compared to the Parent line. By comparison, the lysate prepared from CJ-A only pro-
duced a small amount of phosphorylated [14C]pantothenate in the same time period. The
inset in Fig 6 demonstrates that PanK activity could be detected in CJ-A lysates when the
Fig 4. The fold change in (a) PanOH, (b) CJ-15,801 and (c) chloroquine IC50 values of PanOH-A, PanOH-B and
CJ-A parasite lines, in the absence (black bars) or presence (grey bars) of wild-type PfPanK1 complementation,
relative to that of their corresponding parental lines. Each fold change value is averaged from 3 independent
experiments and error bars represent SEM. An asterisk indicates that the fold change in sensitivity of the mutant is
significantly altered by complementation (PanOH fold change 95% CI: PanOH-A = -5.29 to -2.05, PanOH-B = -6.25 to
-2.26 & CJ-A = -13.00 to -4.62; CJ-15,801 fold change 95% CI: PanOH-A = -4.17 to -0.79, PanOH-B = -6.14 to -1.06 &
CJ-A = -8.05 to -4.22). No change in chloroquine sensitivity was observed (95% CI: PanOH-A = -0.23 to 0.43,
PanOH-B = -0.09 to 0.40 & CJ-A = -0.01 to 0.59). The fold change in the sensitivity to CJ-15,801 for PanOH-B and
CJ-A before and after complementation was calculated using IC35 values.
https://doi.org/10.1371/journal.ppat.1006918.g004
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experiment was carried out in the presence of a 100-fold higher pantothenate concentration
(200 μM) and for an extended time (420 min). These observations provide strong evidence
that the Pfpank1 gene codes for a functional PanK. Further, we generated from the wild-type
3D7 strain a transgenic parasite line that episomally expresses a GFP-tagged copy of PfPanK1
in order to localise the protein within the parasite. We found that PfPanK1 is largely localised
throughout the cytosol of trophozoite-stage parasites, and is not excluded from the nucleus
(Fig 7).
Fig 5. The fitness of the different mutant lines generated in this study relative to the Parent line as determined from parasite
competition assays. (a) A flow chart illustrating how the competition assay was performed. For each competition culture, an equal
number of parasites from the Parent and a mutant line were combined into a single flask. These mixed cultures were maintained
for a period of 6 weeks. The fitness cost associated with the Pfpank1 mutations was assessed by determining the PanOH sensitivity
of the mixed cultures: (b) Parent vs PanOH-A (grey triangles), (c) Parent vs PanOH-B (grey squares) and (d) Parent vs CJ-A (grey
diamonds), at Week 0 (W0; dashed lines) and Week 6 (W6; solid lines). It was expected that the greater the fitness cost to the
mutant, the greater the shift of its mixed culture PanOH dose-response curve toward the Parent line curve after 6 weeks. Arrows
indicate this shift between W0 and W6. The parasite proliferation curves (dotted lines) of the respective mutant clones (black
symbols) and Parent line (white circles) are also shown for comparison. Values for the mixed cultures are averaged from 2
independent experiments, each carried out in triplicate. Error bars represent SEM (n 4) for the individual cultures and range/2
for the mixed cultures, and are not visible if smaller than the symbols.
https://doi.org/10.1371/journal.ppat.1006918.g005
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To investigate further the effects of the PfPanK1 mutations present in the PanOH- and CJ-
15,801-resistant clones, we analysed the PanK activity profiles using lysates prepared from
each mutant and the Parent, and determined their kinetic parameters from the Michaelis-
Menten equation (Fig 8). The apparent pantothenate Km values of the mutant clones are 26–
609-fold higher (95% CI exclude 0) than that of the Parent line. The maximal velocity (Vmax)
of pantothenate phosphorylation by lysates prepared from PanOH-A, PanOH-B and CJ-A are
also significantly higher (95% CI exclude 0) than that of the Parent. To eliminate the possibility
that the elevated Vmax values are due to increased PfPanK1 levels in the mutant parasites, we
used DIA-MS to compare the PfPanK1 level in each of the mutant lines with that of the Parent
parasite. We found that PfPanK1 levels are unchanged in the CJ-A line (95% CI include 0) and
are only elevated by 26 ± 5% and 27 ± 4% (mean ± SEM) in PanOH-A and PanOH-B, respec-
tively (S3 Fig). This modest (or lack of an) increase in PfPanK1 levels is insufficient to explain
the larger increases in Vmax values observed in lysates prepared from the mutant lines, as the
increase in protein levels would need to be ~20-fold for PanOH-A and ~2-fold for PanOH-B
to account for the altered Vmax values. We have therefore not adjusted the observed Vmax val-
ues to account for these small increases in the PfPanK1 levels. We also calculated the PfPanK
relative specificity constant for each parasite line, which indicates the catalytic efficiency of
each variant of PfPanK relative to that of the Parent line. The relative specificity constant
obtained for PanOH-A (0.74 ± 0.04, mean ± SEM) is not significantly different (95% CI
include 0) from that of the Parent. However, those of PanOH-B (0.058 ± 0.004, mean ± SEM)
and CJ-A (0.019 ± 0.005, mean ± SEM) are significantly lower (95% CI exclude 0). These data
are consistent with all three PfPanK1 mutations observed reducing the enzyme’s affinity for
Fig 6. The phosphorylation of [14C]pantothenate (2 μM) over time (in minutes) by lysates generated from Parent
(white circles), PanOH-A (black triangles), PanOH-B (black squares) and CJ-A (black diamonds) parasites.
Inset shows [14C]pantothenate (2 μM supplemented with non-radioactive pantothenate to a total pantothenate
concentration of 200 μM) phosphorylation by CJ-A parasite lysates measured over 420 min. Values are averaged from
3 independent experiments, each performed with a different batch of lysate and carried out in duplicate. Error bars
represent SEM and are not visible if smaller than the symbols.
https://doi.org/10.1371/journal.ppat.1006918.g006
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pantothenate, although the associated increase in the enzyme Vmax compensates for the
reduced affinity: fully in the PanOH-A clone, but to a much lesser extent in PanOH-B and
CJ-A (resulting in a 17-fold and 52-fold reduction in the enzyme’s catalytic efficiency,
respectively).
CJ-A requires a higher extracellular pantothenate concentration
An extracellular supply of pantothenate is essential for the in vitro proliferation of the intraery-
throcytic stage of P. falciparum [8]. Given the impact that the PfPanK1 mutations have on
PanK activity (Fig 8), we set out to determine whether a higher extracellular concentration of
pantothenate is required to support the proliferation of the different mutant clones relative to
that required by the Parent line. As observed in Fig 9A, the proliferation of the Parent line
(white circles) increased as the extracellular pantothenate concentration was increased, reach-
ing the 100% control level (parasites maintained in the presence of 1 μM pantothenate, the
concentration of pantothenate in the complete RPMI medium used to maintain all of the para-
site cultures, which is within the physiologically relevant range in human blood [38,39]) at
approximately 100 nM. In order to compare the extracellular pantothenate requirement
between the different lines, we determined the SC50 (50% stimulatory concentration; i.e. the
concentration of pantothenate required to support parasite proliferation to a level equivalent
to 50% of the control level) values for the mutants (with and without complementation) and
Parent. From Fig 9B, it can be seen that the SC50 values of PanOH-A and PanOH-B are not
different from that of the Parent line (95% CI include 0). Conversely, as illustrated by the right-
ward shift in its dose-response curve (black diamonds, Fig 9A), the pantothenate SC50 of CJ-A
is approximately 3-fold higher than that of the Parent (Fig 9B; 95% CI = 2.7 to 30.9). Further-
more, consistent with the data from the complementation experiments (Fig 4), the SC50 value
Fig 7. Confocal micrographs showing the subcellular location of GFP-tagged PfPanK1 in 3D7 strain parasites harbouring the
Pfpank1-pGlux-1 episomal plasmid. From left to right: Brightfield, GFP-fluorescence, DAPI- (fixed cells; top) or Hoechst 33258- (live
cells; bottom) fluorescence, and merged images of erythrocytes infected with trophozoite-stage P. falciparum parasites expressing
PfPanK1-GFP. Arrows indicate the plasma membranes of either the erythrocytes (black) or the parasites (white). Scale bar represents 5
μm.
https://doi.org/10.1371/journal.ppat.1006918.g007
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of CJ-A+WTPfPanK1 (grey diamonds, Fig 9A) is comparable to that of the Parent line and also
the control line, Parent+WTPfPanK1 (Fig 9B; 95% CI include 0), indicating that the episomal
expression of wild-type PfPanK1 is sufficient to reverse the phenotypic effects of the mutation.
N5-trz-C1-Pan and N-PE-αMe-PanAm have a different mechanism of
action to PanOH and CJ-15,801
To determine whether the resistance of the clones to PanOH and CJ-15,801 extends to other
pantothenate analogues, we tested the mutant clones against the two recently-described,
Fig 8. PfPanK activity profiles derived from the initial rates of pantothenate phosphorylation by lysates generated
from Parent (white circles), PanOH-A (black triangles), PanOH-B (black squares) and CJ-A (black diamonds)
parasites at various pantothenate concentrations. The grey diamond indicates a data point that was outside the 95%
confidence band when it was included in the non-linear regression. This data point was therefore deemed an outlier and was
omitted from the data set used to generate the fitted curve shown. Values are averaged from 3 independent experiments,
each performed with a different batch of lysate and carried out in duplicate. Error bars represent SEM and are not visible if
smaller than the symbols. Relative specificity constant (rsc) values express the specificity constants obtained for each cell line
relative to that of the Parent. The Vmax (μmol/(1012 cells.h)), Km (μM) and rsc values determined from the curves are shown
within each box. Errors represent SEM (n = 3). An asterisk indicates that the value is significantly different compared to the
Parent line (Vmax 95% CI compared to Parent: PanOH-A = 173 to 344, PanOH-B = 5.2 to 21.6 & CJ-A = 112 to 133; Km 95%
CI compared to Parent: PanOH-A = 8.8 to 13.3, PanOH-B = 8.3 to 20.7 & CJ-A = 42 to 484; rsc 95% CI compared to Parent:
PanOH-B = -1.366 to -0.519 & CJ-A = -1.404 to -0.557). No significant difference was observed between the rsc of the
Parent and PanOH-A (95% CI compared to Parent: -0.698 to 0.179).
https://doi.org/10.1371/journal.ppat.1006918.g008
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modified pantothenamides with potent antiplasmodial activities, namely N5-trz-C1-Pan [20]
and N-PE-αMe-PanAm [21]. We found that PanOH-A is 3-fold more sensitive to N5-trz-
C1-Pan, PanOH-B is 2-fold more resistant and CJ-A is 9-fold more resistant when compared
to the Parent line (95% CI exclude 0; Fig 10A and S5 Table, left side). Similarly, we found that
relative to the Parent line, PanOH-A was more sensitive to N-PE-αMe-PanAm (~2-fold),
while CJ-A is 2-fold more resistant (95% CI exclude 0; Fig 10B and S5 Table, left side). The
sensitivity of PanOH-B to N-PE-αMe-PanAm was statistically indistinguishable from that of
the Parent line (95% CI = -0.046 to 0.005; Fig 10B and S5 Table, left side). These results indi-
cate that PfPanK1 can influence the sensitivity of the parasite to multiple antiplasmodial panto-
thenate analogues. Remarkably, the mutation at position 507 of the PfPanK1 in PanOH-A
makes the parasite resistant to the antiplasmodial activity of certain pantothenate analogues
(PanOH and CJ-15,801) whilst at the same time hyper-sensitises the parasite to pantothenate
analogues of a different class (modified pantothenamides, N5-trz-C1-Pan and N-PE-αMe-
PanAm).
Previous work has shown that, in bacteria, pantothenamides are metabolised by the CoA
biosynthetic pathway to form CoA antimetabolites [40], consistent with PanK activity being
important for metabolic activation of pantothenamides. Additionally, it has been reported
recently that pantothenamides are also phosphorylated by the PanK in P. falciparum [41], in
line with their metabolic activation in bacteria. We therefore set out to determine whether the
modified, pantetheinase-resistant, pantothenamides are metabolised and to what extent. In
order to do so, we exposed intact Parent line P. falciparum-infected erythrocytes to N5-trz-
C1-Pan (at ~10 × the IC50 for 4 h) and subjected lysates from the treated (and control) samples
Fig 9. The pantothenate requirement of the different parasite lines observed in this study. (a) Percentage
proliferation of parasites grown in different pantothenate concentrations. Values are averaged from 3 independent
experiments, each carried out in triplicate. Error bars represent SEM and are not visible if smaller than the symbols. For
clarity, only data from the Parent (white circles), CJ-A (black diamonds), and CJ-A+WTPfPanK1 (grey diamonds) lines are
shown. (b) The pantothenate stimulatory concentration 50 (SC50) values obtained for Parent, PanOH-A, PanOH-B,
CJ-A, Parent+WTPfPanK1 and CJ-A+WTPfPanK1 line parasites, which is the concentration of pantothenate required in the
medium to support parasite proliferation by 50% (with 100% set to parasites grown in complete medium containing 1
μM pantothenate). Errors represent SEM (n 3). An asterisk indicates that the value is significantly different from that
obtained for the Parent line (CJ-A SC50 value 95% CI compared to Parent: 2.7 to 30.9). No significant difference was
observed between the SC50 value of the Parent and those of PanOH-A, PanOH-B, Parent
+WTPfPanK1 and CJ-A+WTPfPanK1
(95% CI compared to Parent: PanOH-A = -6.8 to 7.1, PanOH-B = -3.8 to 9.3, Parent+WTPfPanK1 = -9.3 to 3.3 &
CJ-A+WTPfPanK1 = -7.8 to 6.6).
https://doi.org/10.1371/journal.ppat.1006918.g009
PfPanK1 influences antiplasmodial activity of pantothenate analogues
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006918 April 3, 2018 17 / 30
PfPanK1 influences antiplasmodial activity of pantothenate analogues
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006918 April 3, 2018 18 / 30
to untargeted LC-MS. Among the metabolites extracted from parasite-infected erythrocytes
treated with N5-trz-C1-Pan (but not untreated control samples) were molecules with masses
corresponding to phosphorylated N5-trz-C1-Pan ([M-H]- m/z 378.1668), a dephospho-CoA
analogue of N5-trz-C1-Pan ([M-2H]2- m/z 353.6099) and a CoA analogue of N5-trz-C1-Pan
([M-H]- m/z 787.1858) as shown in S4 Fig. This is consistent with N5-trz-C1-Pan being meta-
bolised within infected erythrocytes to generate a CoA antimetabolite.
Lastly, we investigated the ability of the different pantothenate analogues to inhibit the
phosphorylation of [14C]pantothenate by parasite lysates prepared from the various mutant
clones. These data are shown in Fig 10C–10F and S5 Table, right side. All of the analogues
tested are significantly less effective (95% CI exclude 0) at inhibiting pantothenate phosphory-
lation by lysates generated from the mutant clones compared to their ability to inhibit panto-
thenate phosphorylation by lysates prepared from the Parent line. The exception being N-PE-
αMe-PanAm, which did not reach statistical significance when tested against lysate prepared
from PanOH-A. Additionally, the effectiveness of the analogues at inhibiting pantothenate
phosphorylation by lysates prepared from the mutant lines all observe the following order:
PanOH-A > PanOH-B > CJ-A.
Discussion
The putative Pfpank1 gene codes for a functional pantothenate kinase
When PfPanK1 is compared to type II PanKs from other organisms in a multiple protein
sequence alignment, the three nucleotide-binding motifs characteristic of this superfamily can
be seen to be conserved in PfPanK1, consistent with it being a functional PanK [7]. However,
biochemical confirmation of its putative function as a PanK has not been demonstrated. In
this study, we show that mutations in the putative PfPanK1 lead to substantial changes in pan-
tothenate kinase activity (Fig 8) providing, for the first time, biochemical evidence that the
cytosolic PfPanK1 (Fig 7) is a functional pantothenate kinase. Furthermore, the fact that multi-
ple independent experiments aimed at generating parasites resistant to PanOH and CJ-15,801
always selected for mutations in PfPanK1 (Fig 3A and S4 Table) is consistent with the kinase
being the primary PanK involved in the metabolic activation of pantothenate analogues, at
least during the intraerythrocytic stage. Although it is intriguing that PfPanK1 is not excluded
from the nucleus, this phenomenon has been reported for some PanKs in other organisms
[42].
Although it is clear that the PfPanK1 residues at position 95 and 507 are required for nor-
mal PfPanK1 activity (Fig 8), and the PfPanK1 model structure (Fig 3B) shows that both resi-
dues are situated adjacent to the enzyme active site, their exact role(s) in modifying the activity
of the protein is less obvious. The Gly residue at position 95 is conserved in eukaryotic PanKs
[7] and is the residue at the cap of the α2-helix in the inactive conformation of the protein
(S5A Fig). One possibility is that the change to Ala at this position could affect the structure of
the helix and consequently the overall stability of the protein (at least when the protein is in
the inactive state), as Gly has been shown to be much better than Ala at conferring structural
Fig 10. Percentage parasite proliferation of the different lines in the presence of the pantothenate analogues (a)
N5-trz-C1-Pan and (b) N-PE-αMe-PanAm, and inhibition of [14C]pantothenate phosphorylation in parasite
lysates by various pantothenate analogues: (c) PanOH, (d) CJ-15,801, (e) N5-trz-C1-Pan and (f) N-PE-αMe-
PanAm. Symbols represent Parent (white circles), PanOH-A (black triangles), PanOH-B (black squares) and CJ-A
(black diamonds) parasite lines. The Y-axes of c−f indicate the percentage of total pantothenate phosphorylation.
Values are averaged from 3 independent experiments, each carried out in triplicate for the parasite proliferation
assays and duplicate for the phosphorylation assays. Error bars represent SEM and are not visible if smaller than the
symbols.
https://doi.org/10.1371/journal.ppat.1006918.g010
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stability when located at the caps of helices [43]. Alternatively, Gly residues have been shown
to be present at a higher frequency in the active sites of some enzymes where they likely confer
the flexibility to alternate between open and closed conformations [44]. Although the Gly95
residue is not part of the PfPanK1 active site per se, it is within close proximity to the site (Fig
3B), and the α2-helix certainly undergoes a conformational change when PanK switches from
the inactive conformation to the active one [29]. This conformational change is demonstrated
in S5A Fig, which shows an overlay of the human PanK3 crystal structures in the active [29]
and inactive [45] state (Gly95 in PfPanK1 is equivalent to Gly117 in the human enzyme). It is
worth noting that acetyl-CoA (an inhibitor of the enzyme) can only be accommodated in the
binding site when the enzyme is in the inactive state, as when the enzyme is in the active state,
the α2-helix encroaches on the space occupied by acetyl-CoA (S5A Fig). This lends further
support to the importance of this helix for the enzyme to transition from the inactive to the
active state (and vice versa) and, therefore, to the role that Gly95 could play in this process.
Either way, these suggestions may explain why a mutation at this position has a greater impact
on PfPanK1 function than the mutation at position 507. The Asp residue at position 507 is
replaced by a different amino acid (Glu) in most other eukaryotic PanKs, although they are
both negatively-charged [7]. A substitution to the uncharged Asn could disrupt any important
salt-bridges or hydrogen bonds with the residue at this position. In human PanK3, the amino
acid equivalent to Asp507 is Glu354. In the enzyme’s inactive state, Glu354 is within ionic
bonding distance of Arg325, which in turn interacts with the 3’-phosphate of acetyl-CoA (S5B
Fig) [45] and may therefore stabilise the inactive state of the enzyme. Conversely, in the
enzyme’s active state, Glu354 and Arg325 are not within ionic bonding distance (S5B Fig). If
Asp507 in PfPanK1 plays a similar role to that proposed for Glu354 in human PanK3, the
change at position 507 to an Asn (abolishing the negative charge) could prevent stabilisation
of the inactive state, providing an explanation for the increased activity observed in PanOH-A
(Fig 6). Determining the crystal structure of PfPanK1 bound with pantothenate may provide a
better understanding of the roles these residues play in PanK function.
PfPanK1 is essential for normal intraerythrocytic proliferation of P.
falciparum
It has been established that almost all of the 4’-phosphopantothenate found in P. falciparum-
infected erythrocytes is generated within the parasite by PfPanK as part of its metabolism into
CoA [10], which is in line with PfPanK activity being essential for the parasite’s survival. In the
present study, our inability to knock out PfPanK1 (S2 Fig) is consistent with the protein being
essential for the intraerythrocytic stage of P. falciparum, although we cannot exclude the
unlikely possibility that the regions we targeted for the required double-crossover recombina-
tion event are genetically intractable. Our observation that clones PanOH-B and CJ-A, which
harbour mutations at position 95 of PfPanK1, can be outcompeted by the Parent parasites in
competition assays over approximately 20 intraerythrocytic cycles (Fig 5) is consistent with
the mutations incurring a fitness cost. This, in turn, indicates that PfPanK1 is essential for nor-
mal parasite development, at least during the blood stage of its lifecycle. It was also found here
that clone CJ-A requires an approximately 3-fold higher extracellular pantothenate concentra-
tion in order to survive (Fig 9), coinciding with this clone having the PfPanK with the highest
Km. This is not surprising given the reported importance for the substrate concentration to
exceed the enzyme Km for optimal enzyme efficiency [46,47]. More importantly, the require-
ment by this clone for a higher concentration of extracellular pantothenate is also congruent
with PfPanK1 being essential for the normal development of P. falciparum during its asexual
blood stage.
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Our observation that PfPanK1 is essential for normal parasite growth during the blood
stage is at odds with recent reports that show both PanK1 and PanK2 from Plasmodium
yoelli and Plasmodium berghei are dispensable during the blood stage of those parasites [48–
50]. However, both of these murine malaria parasite species preferentially infect reticulo-
cytes [51,52]. Unlike the mature erythrocytes preferred by P. falciparum, reticulocytes have
been shown to provide a rich pool of nutrients for the parasite, allowing the murine para-
sites to survive metabolic or genetic changes that would have been deleterious in P. falcipa-
rum [53]. It is therefore conceivable that unlike the condition faced by P. falciparum, the
reticulocyte-residing parasites are able to salvage sufficient CoA or CoA intermediates from
the host cell for their survival, rendering the two PanK proteins dispensable during their
intraerythrocytic stage, a possibility acknowledged by the authors of the P. berghei study
[49].
PanOH and CJ-15,801 share a common mechanism of action
We have presented data consistent with the observed PfPanK1 mutations being the genetic
basis for the PanOH and CJ-15,801 resistance phenotypes observed in all of the drug-pressured
clones we generated (Fig 4). As shown by the data presented in Fig 10, both PanOH and CJ-
15,801 inhibited pantothenate phosphorylation by the mutated PfPanK1 proteins less effec-
tively than their inhibition of pantothenate phosphorylation by the wild-type PfPanK1 (the
order of their IC50 values is Parent < PanOH-A < PanOH-B < CJ-A). Importantly, this order
is also reflected in the level of resistance of the mutant clones to these two analogues, although
the magnitude is not preserved (Fig 2 and S3 Table). These data are consistent with PfPanK1
being involved in the antiplasmodial activity of these analogues either as a target or a metabolic
activator. Previous studies have demonstrated that the antiplasmodial activity of both PanOH
and CJ-15,801 involves the inhibition of pantothenate phosphorylation by PfPanK [9,15].
More specifically, PanOH has been shown to inhibit PfPanK-mediated pantothenate phos-
phorylation by serving as its substrate [54]. CJ-15,801 is also likely to be a substrate of PfPanK,
especially since it has been shown to be phosphorylated by the S. aureus PanK [55], another
type II PanK [56]. In addition, the same study showed that the second enzyme in the CoA bio-
synthetic pathway, PPCS, subsequently accepts phosphorylated CJ-15,801 as a substrate, and
performs the first step of the PPCS reaction (cytidylylation) on it. However, unlike what
happens with 4’-phosphopantothenate, this cytidylylated phospho-CJ-15,801 acts as a tight-
binding, dead-end inhibitor of the enzyme [55]. A separate study also concluded that
PanOH targets the PPCS enzyme in Escherichia coli and Mycobacterium tuberculosis [57].
Based on the data generated in this study and the published reports that PanOH and CJ-
15,801 both inhibit PPCS in other systems, we propose a similar mechanism of action for
these compounds in P. falciparum, whereby they are phosphorylated by PfPanK1 and subse-
quently block PfPPCS as dead-end inhibitors (Fig 11). The overlapping pattern of cross-
resistance between the two compounds (Fig 2) is also in line with them having a similar
mechanism of action. We propose that the observed resistance to PanOH and CJ-15,801 is
due to the mutated PfPanK1 having a reduced capacity to phosphorylate these analogues
relative to pantothenate. This would have the effect of reducing the amount of phosphory-
lated PanOH or CJ-15,801 generated relative to 4’-phosphopantothenate, thereby allowing
the parasites to survive at higher concentrations of the drugs. Furthermore, our observation
that the mutant clones have comparable levels of PanOH and CJ-15,801 resistance (Fig 2
and S3 Table), despite having PfPanK1 proteins of vastly different efficiency (Fig 8), is likely
due to the pathway flux control at the PfPPCS-mediated step in the CoA biosynthetic path-
way of P. falciparum, as shown in a previous study [32].
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N5-trz-C1-Pan is converted into an antiplasmodial CoA analogue – N-PE-
αMe-PanAm likely shares the same mechanism of action
N5-trz-C1-Pan and N-PE-αMe-PanAm are pantothenamide-mimics that harbour modifica-
tions designed to prevent them from being substrates of pantetheinase, thereby preventing
their degradation: N-PE-αMe-PanAm is methylated at the α-carbon [21] while N5-trz-C1-Pan
harbours a triazole instead of the labile amide [20]. Our LC-MS data clearly show that N5-trz-
C1-Pan is converted into a CoA antimetabolite (S4 Fig), and it is therefore likely to go on to
inhibit/inactivate CoA-utilising enzymes, killing the parasite. Such a mechanism has previ-
ously been put forward to explain the antibiotic activity of two prototypical pantothenamides
(N5-Pan and N7-Pan) whereby the compounds are phosphorylated by PanK and subsequently
metabolised by PPAT and DPCK to generate analogues of CoA (ethyldethia-CoA and butyl-
dethia-CoA) [40,58,59]. These CoA analogues then mediate their antibacterial effect/s primar-
ily by inhibiting/inactivating CoA-requiring enzymes and acyl carrier proteins [40,58,59].
Similarly, phospho-N5-trz-C1-Pan is not expected to interact with PfPPCS because it lacks the
carboxyl group (Fig 1) required for the nucleotide activation by nucleotide transfer [55]. It is
Fig 11. The proposed antiplasmodial mechanisms of action of various pantothenate analogues in Plasmodium
falciparum. PanOH and CJ-15,801 (orange) are phosphorylated by PfPanK and their phosphorylated forms
accumulate (indicated by the bigger font) and then competitively inhibit PfPPCS. The step mediated by PfPPCS has
been hypothesised to be a pathway flux control point (illustrated by the red box) in the CoA biosynthesis pathway. On
the other hand, we propose that although N-PE-αMe-PanAm and N5-trz-C1-Pan (cyan) are also phosphorylated by
PfPanK, they then bypass PfPPCS and PfPPCDC (as shown previously in bacteria) and rejoin the pathway as substrates
of PfPPAT and then PfDPCK, resulting in the generation and accumulation of CoA antimetabolites. These CoA
antimetabolites exert their antiplasmodial activity by inhibiting CoA-dependent processes.
https://doi.org/10.1371/journal.ppat.1006918.g011
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therefore expected to bypass the PfPPCS and PfPPCDC steps of the CoA biosynthetic pathway
on its way to being converted into the CoA antimetabolite version of N5-trz-C1-Pan (Fig 11).
Furthermore, the antiplasmodial activity rank order of N5-trz-C1-Pan against the various
mutant clones is very similar to that of N-PE-αMe-PanAm – with PanOH-A being hypersensi-
tive to both compounds, CJ-A resistant to both and PanOH-B, by comparison, exhibiting only
small changes in sensitivity to the two compounds (Fig 10A and 10B) – and is starkly different
to those of PanOH and CJ-15,801 (Fig 2). These are congruent with (i) the antiplasmodial
mechanism of action of N-PE-αMe-PanAm being similar to that of N5-trz-C1-Pan and (ii) the
antiplasmodial mechanism of action of N-PE-αMe-PanAm and N5-trz-C1-Pan being different
to that of PanOH and CJ-15,801.
The order of antiplasmodial activity of N5-trz-C1-Pan and N-PE-αMe-PanAm against the
mutant clones can be explained on the basis of (i) the difference in the rate of PfPanK1 activity
in the various clones at the concentrations of pantothenate and N5-trz-C1-Pan / N-PE-αMe-
PanAm used (Fig 6), (ii) the fact that the PfPPCS-mediated step imposes pathway flux control
[32] and (iii) the fact that this pathway flux control is bypassed by N5-trz-C1-Pan (and almost
certainly also by N-PE-αMe-PanAm) en route to its conversion into a CoA antimetabolite. As
seen in Fig 6, in the presence of 2 μM pantothenate (a similar concentration to the 1 μM pres-
ent in the antiplasmodial assay), the pantothenate phosphorylation rate of the different clones
has the following rank order: PanOH-A > Parent > PanOH-B > CJ-A, approximately the
inverse of the antiplasmodial IC50 values of N5-trz-C1-Pan and N-PE-αMe-PanAm (described
above). Therefore, PanOH-A, for example, would be expected to generate more 4’-phospho-
pantothenate and phosphorylated N5-trz-C1-Pan (or N-PE-αMe-PanAm), based on the
assumption that the mutation also leads to increased phosphorylation activity towards the pan-
tothenate analogues (point i). Whilst the increased levels of 4’-phosphopantothenate would
not be expected to result in a concomitant increase in CoA (due to the pathway flux control at
PfPPCS; point ii), the increased production of phospho-N5-trz-C1-Pan would result in
increased levels of the N5-trz-C1-Pan CoA antimetabolite as the flux control step is bypassed
(point iii). This would explain the increased sensitivity of PanOH-A to both N5-trz-C1-Pan
and N-PE-αMe-PanAm and also the sensitivity rank order of the other parasite lines.
In conclusion, our study confirms for the first time that PfPanK1 functions as the active
pantothenate kinase in the asexual blood stage of P. falciparum. Our data show that the sites of
mutation in PfPanK1 reported here are important residues for normal PfPanK function and
are essential for normal intraerythrocytic parasite growth, although further structural and
functional studies are required to elucidate their exact role(s). Furthermore, we propose that
following phosphorylation by PfPanK1, PanOH and CJ-15,801 compete with 4’-phosphopan-
tothenate and serve as dead-end inhibitors of PfPPCS (depriving the parasite of CoA). In con-
trast, N-PE-αMe-PanAm and N5-trz-C1-Pan are further metabolised (by PfPPAT and
PfDPCK) into CoA analogues that kill the parasite by inhibiting CoA-utilising metabolic pro-
cesses. Finally, we provide the first genetic evidence consistent with pantothenate analogue
activation being a critical step in their antiplasmodial activity.
Supporting information
S1 Materials and methods. Additional information about materials and methods used in
the study.
(DOCX)
S1 Table. List of oligonucleotides used in this study. MCS: Multiple Cloning Site.
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S2 Table. Sequences of peptides used to identify and quantify the five proteins of interest
shown in S3 Fig. aCertainty of peptide identification.
(DOCX)
S3 Table. Inhibition of the proliferation of Parent, PanOH-A, PanOH-B, CJ-A, Parent+-
WTPfPanK1, PanOH-A+WTPfPanK1, PanOH-B+WTPfPanK1 and CJ-A+WTPfPanK1 parasites by
PanOH, CJ-15,801 and chloroquine, as represented by IC50 values. Errors represent SEM
(n 3). The averaged CJ-15,801 IC50 value for PanOH-B (n = 3) includes a single extrapolated
value, because in one experiment the highest concentration tested (800 μM) did not inhibit
parasite growth by 50%. An asterisk indicates that the IC50 value of the mutant line is signifi-
cantly different from that obtained for the Parent line (PanOH IC50 95% CI compared to Par-
ent IC50: PanOH-A = 2664 to 3432, PanOH-B = 3553 to 4552 & CJ-A = 6046 to 7456; CJ-
15,801 IC50 95% CI compared to Parent IC50: PanOH-A = 296 to 436, PanOH-B = 495 to 717
& CJ-A = 688 to 823). The chloroquine IC50 values of the different lines are indistinguishable
(95% CI compared to Parent IC50: PanOH-A = -2.023 to 1.646, PanOH-B = -2.114 to 0.492 &
CJ-A = -2.507 to 0.158).
(DOCX)
S4 Table. List of non-synonymous single nucleotide polymorphisms found in the
PanOH-A, PanOH-B and CJ-A parasite lines as determined by whole genome sequencing
and variant calling using the PlaTyPus integrated pipeline. Uppercase letters in the “Codon
Change” column denotes the base within the codon that has been altered in the coding
sequence before/after the mutation. The deletion in PanOH-B at position 95 is not included
here because PlaTyPus is unable to detect insertions-deletions polymorphisms.
(DOCX)
S5 Table. Inhibition of the proliferation of Parent, PanOH-A, PanOH-B and CJ-A para-
sites by N5-trz-C1-Pan and N-PE-αMe-PanAm, and the inhibition of [14C]pantothenate
phosphorylation in parasite lysates (generated from the same lines) by the pantothenate
analogues PanOH, CJ-15,801, N5-trz-C1-Pan and N-PE-αMe-PanAm, as represented by
IC50 values. Errors represent SEM (n 3). An asterisk indicates that the value is significantly
different from that obtained for the Parent line (95% CI of N5-trz-C1-Pan proliferation inhibi-
tion IC50 compared to Parent: PanOH-A = -0.088 to -0.038, PanOH-B = 0.047 to 0.121 &
CJ-A = 0.715 to 0.824; 95% CI of PE-αMe-PanAm proliferation inhibition IC50 compared to
Parent: PanOH-A = -0.060 to -0.008 & CJ-A = 0.024 to 0.076; 95% CI of PanOH phosphoryla-
tion inhibition IC50 compared to Parent: PanOH-A = 46 to 69, PanOH-B = 71 to 263 &
CJ-A = 4531 to 5300; 95% CI of CJ-15,801 phosphorylation inhibition IC50 compared to Par-
ent: PanOH-A = 10 to 309 & PanOH-B = 330 to 621; 95% CI of N5-trz-C1-Pan phosphoryla-
tion inhibition IC50 compared to Parent: PanOH-A = 6.5 to 13 & PanOH-B = 9.8 to 30; 95%
CI of N-PE-αMe-PanAm phosphorylation inhibition IC50 compared to Parent: PanOH-B = 3.6
to 9.0 & CJ-A = 75 to 97).
(DOCX)
S1 Fig. Quantitative PCR analysis of gDNA samples extracted from the three competition
assay cultures generated in the study, Parent vs PanOH-A, Parent vs PanOH-B and Parent
vs CJ-A (Fig 5). Data are shown as the proportions of mutant gDNA (out of a 100% total) at
week 0 and week 6. Values are averaged from two independent competition assays, each ana-
lysed by qPCR in duplicate. Error bars represent range/2.
(TIF)
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S2 Fig. The attempt at knocking-out Pfpank1 in wild-type 3D7 parasites through homolo-
gous integration. (a) Schematic representations of the ΔPfpank1-pCC-1 construct and the
wild-type Pfpank1 gene locus before and after either a homologous double crossover integra-
tion of the hdhfr cassette of ΔPfpank1-pCC-1 or a 5’/3’ single crossover homologous integra-
tion of the ΔPfpank1-pCC-1 construct. The positions of AflII restriction sites are indicated.
The 5’ Pfpank1 and 3’ Pfpank1 homologous flanks are indicated by translucent blue boxes. (b)
Southern blot of AflII-digested gDNA extracted from wild-type parasites and from ΔPfpank1-
pCC-1-transfectants resistant to WR99210 or both WR99210 and 5-fluorocytosine (5-FC)
after one or two rounds of WR99210 cycling. (i) and (ii) represent independently-selected
drug-resistant cultures. The blot was probed with the 3’ Pfpank1 flank (as indicated by the
black bar in (a)). The probe hybridised to fragments that correspond to the 3D7 wild-type (3.3
kb) and the plasmid (8.9 kb). The fragment that is consistent with a homologous double cross-
over-disrupted locus (3.8 kb) was not detected in either independent culture. hdhfr: human
dihydrofolate reductase—conveys resistance to WR99210. Scfcu: Saccharomyces cerevisiae
cytosine deaminase/phosphoribosyl transferase—conveys sensitivity to 5-FC. (c) PCR confir-
mation that a Pfpank1 knockout event cannot be detected, even in a small sub-population of
parasites. Samples from the same parasite populations shown in (b) were used to generate
DNA templates that were then used with primers selected to amplify a product of 1.9 kb from
the wild-type sequence and a 3.6 kb product from parasites with the Pfpank1 gene knocked out
(and replaced with the hdhfr gene). A PCR product consistent with the size expected for ampli-
fication from the wild-type sequence was observed (black arrow). The identity of this product
was confirmed by sequencing. All the reactions generated an approximately 1.1 kb PCR prod-
uct and some reactions, under certain conditions, produced fainter PCR products likely due to
non-specific primer binding. Importantly, no product of a size consistent with that expected
for a Pfpank1 knockout (3.6 kb) was observed in any of the samples. These data, therefore, are
consistent with those presented in the Southern blot (b).
(TIF)
S3 Fig. Abundance of (a) PfPanK1 and (b) various control proteins (PfPanK2, PfHSP70,
PfHK and Pfα-tubulin) in Parent, PanOH-A, PanOH-B and CJ-A line trophozoites. Pro-
tein levels are determined by LC-MS/MS followed by DIA analysis. Values are averaged
from 3 independent parasite preparations and error bars represent SEM. An asterisk indi-
cates that the protein peak intensity measured for a mutant line is significantly different from
that obtained for the Parent line (95% CI of PfPanK1 protein level compared to Parent:
PanOH-A = 3.87 × 103 to 1.18 × 105 & PanOH-B = 8.86 × 103 to 1.18 × 105). The protein abun-
dance of PfPanK1 in CJ-A (95% CI compared to Parent = -3.38 × 104 to 1.01 × 105) and those of
the housekeeping proteins in all three mutant lines are indistinguishable from the Parent line lev-
els (95% CI for PfPanK2 level compared to Parent: PanOH-A = -1.81 × 104 to 2.53 × 104,
PanOH-B = -1.52 × 104 to 2.25 × 104 & CJ-A = -3.43 × 104 to 1.99 × 104; 95% CI for PfHSP70
level compared to Parent: PanOH-A = -8.98 × 107 to 9.72 × 107, PanOH-B = -6.92 × 107 to
6.27 × 107 & CJ-A = -1.45 × 108 to 1.45 × 108; 95% CI for PfHK level compared to Parent:
PanOH-A = -4.41 × 105 to 2.79 × 106, PanOH-B = -1.18 × 105 to 2.47 × 106 & CJ-A = -2.42 × 106
to 2.13 × 106; 95% CI for Pfα-tubulin level compared to Parent: PanOH-A = -5.57 × 106 to
7.45 × 106, PanOH-B = -4.47 × 106 to 4.25 × 106 & CJ-A = -1.18 × 107 to 2.22 × 106).
(TIF)
S4 Fig. Extracted ion chromatograms (i) and mass spectra (ii) of N5-trz-C1-Pan (a) and
downstream metabolites (b–d). Extracted ion chromatograms (i) show the relative intensity
of each LC peak. Red lines represent metabolites extracted from N5-trz-C1-Pan-treated para-
sites and blue lines represent those extracted from DMSO-treated parasite control samples,
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each carried out in quadruplicate. High resolution mass spectra (ii) of each compound ionised
in negative mode: (a) N5-trz-C1-Pan (C14H26N4O3). Theoretical m/z = 297.1932. Observed m/
z = 297.1942. Δppm = 3.36. (b) Phosphorylated N5-trz-C1-Pan (C14H27N4O6P). Theoretical
m/z = 377.1595. Observed m/z = 377.1594. Δppm = -0.27. (c) Dephospho-CoA N5-trz-C1-Pan
analogue (C24H39N9O12P2). Theoretical m/z = 352.6024. Observed m/z = 352.6024.
Δppm = 0.0. (d) CoA N5-trz-C1-Pan analogue (C24H40N9O15P3). Theoretical m/z = 786.1784.
Observed m/z = 786.1780. Δppm = -0.51. Data shown are from a single experiment representa-
tive of two independent experiments.
(TIF)
S5 Fig. The human PanK3 protein structure in its inactive conformation (yellow; PDB ID:
3MK6) overlaid onto its active conformation (blue; PDB ID: 5KPR). The amino acid resi-
dues of the human protein at positions 117 (indicated by the spheres in a) and 354 (side chains
shown in b) correspond to the mutated residues of PfPanK1 reported in this study (at positions
95 and 507, respectively). (a) The red arrow indicates the change in the conformation of the
α2-helix between the inactive and active states. The altered configuration in the active state
transitions the mutated glycine that corresponds to position 117 away from the end cap of the
α2-helix. (b) Dashed grey lines (inactive conformation) and the solid arrow (active conforma-
tion) represent distances between residue side chains and/or acetyl-CoA (in Å) in PanK3. A
relay of interactions between Glu354, Arg325 and the 3’-phosphate of acetyl-CoA may stabilise
the inactive state of the enzyme. However, in the protein’s active conformation, Glu354 and
Arg325 are not within bonding distance ( 4.4 Å).
(TIF)
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